Immunome grants 9,897 director stock options

Immunome Inc. director-related entity receives new stock option grant.

Rhea-AI Filing Summary

Immunome Inc. director-related entity receives new stock option grant. A director stock option covering 9,897 shares of Immunome common stock was granted at an exercise price of $18.16 per share, expiring on June 9, 2036. The filing lists director Isaac Barchas as reporting person, but he has agreed that any securities granted for his board service are held for the benefit of Arsenal Bridge Ventures, and he disclaims beneficial ownership and all rights in the reported securities.

The option vests in four equal quarterly installments starting on June 10, 2026, through the one-year anniversary, with each vesting date tied to continued service with Immunome. After this award, the reported derivative position in these options is 9,897 units.

Insider Trade Summary

Grant/Award: 9,897 shares

Grant/Award 1 txn

Insider Barchas Isaac

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (right to buy)	9,897	$0.00	$0.00

Holdings After Transaction: Director Stock Option (right to buy) — 9,897 contracts (Direct)

Footnotes (2)

1. F1. Mr. Barchas has agreed to receive and hold for the benefit of Arsenal Bridge Ventures any securities granted to him for his service as a director on the Company's board of directors. As such, Mr. Barchas disclaims beneficial ownership of, and all right, title and interest in, the reported securities.
2. F2. The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to Mr. Barchas' continuous service with the Company on each respective vesting date.

Key Figures

Option grant size: 9,897 options Exercise price: $18.16 per share Expiration date: June 9, 2036 +2 more

5 metrics

Option grant size 9,897 options Director stock option covering common stock

Exercise price $18.16 per share Strike price of director stock option

Expiration date June 9, 2036 Option term end date

Post-transaction derivative holdings 9,897 options Total options held in this award after grant

Vesting schedule 4 equal quarterly installments From June 10, 2026 over one year, service-based

Key Terms

Director Stock Option (right to buy), beneficial ownership, vests in four equal quarterly installments, exercise price, +1 more

5 terms

Director Stock Option (right to buy) financial

"security_title: "Director Stock Option (right to buy)""

beneficial ownership financial

"Mr. Barchas disclaims beneficial ownership of the reported securities"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

vests in four equal quarterly installments financial

"The option vests in four equal quarterly installments, commencing from June 10, 2026"

exercise price financial

"conversion_or_exercise_price: "18.1600""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-06-09T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Immunome (IMNM) report for Isaac Barchas?

Immunome reported a grant of 9,897 director stock options linked to Isaac Barchas’ board service. The options allow purchase of common stock at $18.16 per share and are structured as compensation, not an open‑market trade.

Who ultimately benefits from the new Immunome (IMNM) stock options?

According to the disclosure, Isaac Barchas has agreed that securities granted for his director service are held for the benefit of Arsenal Bridge Ventures. He disclaims beneficial ownership and all right, title, and interest in the reported option award.

How many Immunome (IMNM) shares are covered by the director stock option?

The director stock option covers 9,897 shares of Immunome common stock. This entire amount is reflected as the derivative position following the transaction, representing the full size of the new compensation-related grant reported.

What is the exercise price and expiration of the Immunome (IMNM) option grant?

The option has an exercise price of $18.16 per share and expires on June 9, 2036. This means the holder can choose to buy Immunome common shares at that fixed price any time before the expiration date, subject to vesting.

How does the Immunome (IMNM) director stock option vest over time?

The option vests in four equal quarterly installments starting on June 10, 2026. Vesting continues each succeeding fiscal quarter for one year, and each installment requires Isaac Barchas’ continuous service with Immunome on the applicable vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 05:48 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Barchas Isaac

(Last) (First) (Middle)

C/O IMMUNOME, INC.

18702 N. CREEK PARKWAY, SUITE 100

(Street)

BOTHELL WASHINGTON 98011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunome Inc. [ IMNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	$18.16	06/10/2026		A		9,897(1)		(2)	06/09/2036	Common Stock	9,897	$0	9,897	D

Explanation of Responses:

1. Mr. Barchas has agreed to receive and hold for the benefit of Arsenal Bridge Ventures any securities granted to him for his service as a director on the Company's board of directors. As such, Mr. Barchas disclaims beneficial ownership of, and all right, title and interest in, the reported securities.

2. The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to Mr. Barchas' continuous service with the Company on each respective vesting date.

	/s/ Sandra Stoneman, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)